However, extensive data on patients with AF and the small cancer patient cohort in the AVERT trial suggest that the association between GDF-15 and bleeding risk is at least as strong, if not stronger, in patients receiving anticoagulation compared with those not receiving anticoagulation. Here, GDF15 is linked to atrial fibrillation.